Medical Education May Improve Care for Breast Cancer Minority Populations

Commentary
Video

Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.

Following the publication of her study showing various gaps and racial disparities associated with guideline-concordant care receipt for inflammatory breast cancer (IBC), Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS, spoke with CancerNetwork® about potential institutional solutions for mitigating these health inequities.

According to Fayanju, clinicians may systematically underdiagnose IBC in racial minority populations due to a potential inability to recognize erythema and similar symptoms in patients with darker skin tones. She consequently emphasized greater medical education for primary care providers, surgical oncologists, and other clinicians to recognize how different populations may present with IBC while employing written and photographic documentation for those with suspected abnormalities, thereby ensuring more accurate diagnoses and treatment strategies upfront.

Fayanju is the Helen O. Dickens Presidential Associate Professor, chief in the Division of Breast Surgery at Penn Medicine, surgical director of Rena Rowan Breast Center, director of Health Equity Innovation at Penn Center for Cancer Care Innovation (PC3I), and senior fellow at Leonard Davis Institute of Health Economics (LDI), Perelman School of Medicine at the University of Pennsylvania.

Transcript:

In IBC, there’s a concern that it is systematically underdiagnosed or delayed in its diagnosis in people with darker skin because people may not recognize the classic signs of erythema and peau d’orange in people who have black and brown skin. It’s going to be really important to continue with medical education. That means that primary care providers, obstetrics and gynecology [OB/GYN oncologists], as well as oncologists and surgeons, are not treating something that’s inflammatory as an infection or some type of lymphedema; [it means] that they recognize it to be IBC and act accordingly.

I believe, a lot, in picture documentation. If you suspect it, actually taking a picture and putting it in a chart allows for an objective comparison from visit to visit, for someone who might be suspected to have abnormality. That way, we can be surer about IBC diagnoses upfront and treat them appropriately vs treating them like a locally advanced cancer that may not receive the same sequence of guideline concordant care that I already described. As I said, [there needs to be] education of of physicians as well as of surgeons and medical oncologists to recognize what IBC looks like in diverse individuals, [and] standard documentation, photographic as well as written, of symptoms that are consistent with IBC so we can track people and treat them appropriately.

Then, [providers must] understand the context in which patients receive treatment. I’m a researcher who looks at social determinants of health, and I’m also very interested in the ways in which patients receive care and engage in shared decision-making. [Providers should] make sure that patients understand why we’re proposing certain treatment regimens, why the sequence of treatment matters, and then anticipate any barriers to treatment receipt that might arise as a result of patients’ circumstances, their feelings towards the medical industry, or the ways in which we deliver information about care that may not be well received and may cause them to forego life-saving treatment.

Reference

Tadros A, Diskin B, Sevilimedu V, et al. Trends in guideline-concordant care for inflammatory breast cancer. JAMA Netw Open. 2025;8(2):e2454506. doi:10.1001/jamanetworkopen.2024.54506

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.